Figure 2.
(A) Schematic representation of targeted therapies and immunotherapies that are being investigated in patients with CCA and are in more advanced studies. Resistance mechanisms have been described for some of them as has been discussed. (B) Schematic representation of the types of patient samples that can be used for molecular profiling to select the best targeted therapy for each patient at different times.
